Yahoo HomeBe Kind: Local artist surprises ER nurse
A Delaware artist pulled off an incredible surprise.
Make Yahoo Your Homepage
Discover something new every day from News, Sports, Finance, Entertainment and more!
A Delaware artist pulled off an incredible surprise.
Carlos Rodón threw the majors' second no-hitter of the season Wednesday night, losing his bid for a perfect game on a hit batter in the ninth inning, and the Chicago White Sox cruised to an 8-0 victory over the Cleveland Indians. Working quickly in short sleeves with the top of his jersey unbuttoned on a cool Chicago night, Rodón threw 75 of his 114 pitches for strikes. The No. 3 pick in the 2014 amateur draft out of North Carolina State struck out seven in his first career shutout and second complete game.
NEW YORK, April 14, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX) and certain of its officers. The class action, filed in the United States District Court for the Western District of New York, and docketed under 21-cv-00413, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquire Athenex common stock between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”). This action is brought on behalf of the Class for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”), 15 U.S.C. §§ 78j(b) and 78t(a) and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission, 17 C.F.R. § 240.10b-5. If you are a shareholder who purchased Athenex securities during the Class Period, you have until May 3, 2021 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. [Click here for information about joining the class action] Athenex is a “global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer.” Athenex is “organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform.” One of the Company’s main drug candidates is an oral paclitaxel and encequidar for the treatment of metastatic breast cancer. On August 7, 2019, Athenex announced topline data showing that oral paclitaxel and encequidar met the primary efficacy endpoint with statistically significant improvement over IV paclitaxel in a Phase 3 pivotal study in metastatic breast cancer. In this release, the Company stated that it intended to seek a pre-New Drug Application (“NDA”) meeting with the U.S. Food and Drug Administration (“FDA”) and would “be preparing our NDA submission as soon as possible.” Over the next several months, Defendants continued to laud their Phase 3 study of oral paclitaxel plus encequidar. On September 1, 2020, the Company announced that the FDA had accepted for filing Athenex’s NDA for Oral Paclitaxel and Encequidar in metastatic breast cancer with priority review. In this release, Athenex announced that the FDA had set a target action date of February 28, 2021 for the Company’s NDA, and that “the FDA has communicated that it is not currently planning to hold an advisory committee meeting to discuss the application.” Then, on December 9, 2020, Athenex announced that it had presented updated Phase 3 data on survival and tolerability associated with Oral Paclitaxel and Encequidar in patients with metastatic breast cancer. The Company announced that it had presented this Phase 3 data at the 2020 San Antonio Breast Cancer Symposium, and that the data “demonstrat[ed] clinical benefits in efficacy and tolerability of oral paclitaxel versus IVP in patents with metastatic breast cancer . . . . The findings further support the superiority of increased ORR [objective response rate] observed with oral paclitaxel.” The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business. Specifically, Defendants made false and/or misleading statements and/or failed to disclose: (i) the data included in the Oral Paclitaxel plus Encequidar NDA presented a safety risk to patients in terms of an increase in neutropenia-related sequalae; (ii) the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by BICR; (iii) the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR; (iv) that the Company’s Phase 3 study that was used to file the NDA was inadequate and not well-conducted in a patient population with metastatic breast cancer representative of the U.S. population, such that the FDA would recommend a new such clinical trial; (v) as a result, it was foreseeable that the FDA would not approve the Company’s NDA in its current form; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times. Before the markets opened on March 1, 2021, Athenex issued a press release entitled “Athenex Receives FDA Complete Response Letter for Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer.” In this release, Athenex noted that the “FDA Issues a CRL to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form.” This release further provided that “[i]n the CRL, the FDA indicated its concern of safety risk to patients in terms of an increase in neutropenia-related sequalae on the Oral Paclitaxel arm compared with the IV paclitaxel arm.” In this March 1, 2021 press release, Athenex further stated that the “FDA also expressed concerns regarding the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by blinded independent centra review (BICR). The [FDA] stated that the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR.” Last, in this release, Athenex wrote that the FDA “recommended that Athenex conduct a new adequate and well-conducted clinical trial in a patient population with metastatic breast cancer representative of the population of the U.S. The [FDA] determined that additional risk mitigation strategies to improve toxicity, which may involve dose optimization and / or exclusion of patients deemed to be at a higher risk of toxicity, are required to support potential approval of the NDA.” On this news, the price of Athenex’s shares plummeted from their February 26, 2021 closing price of $12.10 per share to a March 1, 2021 close of just $5.46 each. This represents a one-day drop of approximately 55%, representing hundreds of millions of dollars in lost market capitalization. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com CONTACT:Robert S. WilloughbyPomerantz LLPrswilloughby@pomlaw.com888-476-6529 ext. 7980
(Bloomberg) -- Most Asian equities dipped Thursday after U.S. indexes eased from all-time peaks, with the drop in cryptocurrency exchange Coinbase Global Inc. overshadowing strong bank earnings. Oil trimmed earlier gains.Shares fell in Hong Kong and China as the central bank effectively drained cash from the financial system, adding to concerns about tightening liquidity. Tech stocks also struggled. Japan and South Korea edged higher. U.S. futures fluctuated after Coinbase traded down in its Nasdaq debut. Bank stocks gained overnight on revenue windfalls for the likes of Goldman Sachs Group Inc.The dollar inched upward after three straight days of losses, and the benchmark 10-year Treasury yield held around 1.63%.In Asia’s session, investors are also watching for further tremors from the sharp selloff in the bonds of distressed-debt enterprise China Huarong Asset Management Co., which has pushed investment-grade spreads higher.With equities hovering around record levels, traders are watching the earnings season for further catalysts. Expectations for a strong profit rebound have buoyed indexes, setting the bar high as reporting gets underway. More broadly, investors are alert to any setbacks to the economic recovery from spikes in Covid-19 infections and troubled vaccine rollouts.“You’re going to see this tug-of-war continue within markets as investors weigh the prospects of a strengthening economy with the risk of rising inflationary pressures,” said Adam Phillips, managing director of portfolio strategy at EP Wealth Advisors.The Federal Reserve remains committed to supporting the recovery, and will start tapering asset purchases “well before” policy makers consider raising interest rates, Chairman Jerome Powell told the Economic Club of Washington Wednesday.Bitcoin touched a record of $64,870 before slipping. Oil trimmed an overnight surge but remained around $63 a barrel as shrinking crude stockpiles in the U.S. supported hopes for a global demand recovery.Some key events to watch this week:U.S. data including initial jobless claims, industrial production and retail sales come Thursday.China economic growth, industrial production and retail sales figures are on Friday.These are some of the main moves in financial markets:StocksS&P 500 futures edged up 0.1% as of noon in Tokyo. The index closed down 0.4%.Japan’s Topix Index was up 0.4%.The Shanghai Composite slipped 1.1%.The Hang Seng was down 1.1%.South Korea’s Kospi Index rose 0.2%.Australia’s S&P/ASX 200 Index added 0.1%.CurrenciesThe Bloomberg Dollar Spot Index rose less than 0.1%.The euro was at $1.1974.The Japanese yen was little changed at 108.92 per dollar.The offshore yuan was at 6.5410 per dollar, down 0.1%.BondsThe yield on 10-year Treasuries was at 1.63%.Australia’s 10-year yield was up three basis points to 1.78%.CommoditiesWest Texas Intermediate crude slipped 0.1% to $63.07 a barrel.Gold added 0.2% to $1,739 an ounce.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Jesus Aguilar drove in the winning run with a 10th-inning double and the Miami Marlins overcame two homers by Ronald Acuña Jr. for their third straight win in Atlanta, beating the Braves 6-5 Wednesday night after squandering a 5-0 lead. Leading off in extra innings with Starling Marte placed at second, Aguilar dumped a low pitch from Tyler Matzek (0-1) down the left-field line to bring home the tiebreaking run.
The U.S. Senate Homeland Security and Government Affairs Committee will hold an April 22 hearing on President Joe Biden's three nominees to serve on the U.S. Postal Board of Governors, the panel announced Wednesday. The announcement comes after the U.S. Postal Service (USPS) in March outlined a proposed 10-year strategic plan that would slow current first-class delivery standards and raise some prices to stem $160 billion in forecasted red ink over the next decade. The plan has drawn criticism from many U.S. lawmakers including some calling for the board to fire Postmaster General Louis DeJoy and others who have urged Biden to remove the existing board members.
McGregor was investigated following an alleged "sexual assault and sexual exhibition" incident in France last September.
Apr. 14—ALBUQUERQUE, N.M. — As a public comment period on the federal mineral leasing program draws to a close today, environmental and Indigenous groups in New Mexico's oil and gas-producing communities are seeking a complete overhaul of the system. Julia Bernal, a Sandia Pueblo member and Pueblo Action Alliance director, said during a panel discussion Wednesday that previous administrations ...
NEW YORK, April 14, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Aquestive and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On September 25, 2020, Aquestive announced receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) “regarding the New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film for management of seizure clusters.” Aquestive advised investors that “[i]n the CRL, the FDA cited that, in a study submitted by the Company with the NDA, certain weight groups showed a lower drug exposure level than desired. The Company intends to provide to the FDA additional information on PK modeling to demonstrate that dose adjustments will obtain the desired exposure levels.” On this news, Aquestive’s stock price fell $2.64 per share, or 34.69%, to close at $4.97 per share on September 28, 2020. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com. CONTACT:Robert S. WilloughbyPomerantz LLPrswilloughby@pomlaw.com888-476-6529 ext. 7980
Apr. 14—SANTA FE — New MexiCann Natural Medicine was fined $142,348 by the New Mexico Environment Department and could have its medical cannabis producer license revoked due to violations of the Occupational Health and Safety Act as a result of an October 2020 explosion that injured two workers. The company was cited for six violations, including failures to implement a respirator program, ...
Apr. 14—A McAlester woman was charged this week in tribal court after being accused in 2019 of abusing and neglecting a 5-year-old boy investigators said looked like "a 75-year-old man" when examined at the hospital. Paula Amber Chisholm, 35, was charged Tuesday with child abuse and child neglect, according to documents filed in Choctaw Nation District Court. Chisholm was originally charged in ...
Apr. 14—SANTA FE — Residents of the upscale Las Campanas area north of Santa Fe can expect improved cellphone service in the future. The Santa Fe County Commission voted 4-1 to approve a 70-foot tall Verizon Wireless cell tower on Tuesday, overturning a decision by the Planning Commission not to allow a height variance for the tower. Currently, that area of the county has poor to nonexistent ...
Apr. 14—Ohio and Michigan joined states across the country in temporarily suspending the use of the single-dose Johnson & Johnson coronavirus vaccine in accordance with the federal recommendation while authorities investigate reports of potentially dangerous blood clots. Gov. Mike DeWine stressed in a news conference Tuesday that the pause is expected to be brief — days to maybe a couple weeks ...
Hall of Famer Brett Favre made the comments in wake of Major League Baseball's decision to move the All-Star Game over Georgia's new voting laws.
Apr. 14—A 35-year-old Enid woman was arrested Monday evening on a felony warrant for assault and battery with a dangerous weapon. Michealle Lynn Clark was arrested and charged in relation to the April 3 stabbing of a woman in the neck and thigh at a residence in the 200 block of East Wabash, according to Enid Police Department. At 11:43 p.m. on April 3, officers responded to a hospital ...
Apr. 14—ENID, Okla. — While the U.S. government has expanded its Medicaid benefits to people from Micronesian nations in the Pacific Ocean, Oklahoma has yet to catch up to allow these residents to actually apply before state program expansions begin this summer. The long-awaited expansion of federal health benefits is being called a "good beginning" for the people in Enid's Micronesian ...
Apr. 14—Enid Police Department, in conjunction with Oklahoma Highway Patrol and other local law enforcement agencies, will conduct saturation patrols for DUI enforcement Friday. EPD is asking those who plan to drink Friday to make arrangements for alternate ways home, whether through a designated driver or a ride-share service like Uber or Lyft. "The Enid Police Department wants the community ...
Apr. 14—ALBUQUERQUE, N.M. — A state loan program that launched last year to help businesses hurt by the pandemic will soon be returning, with a new influx of state money and expanded eligibility requirements. Starting April 29, businesses and nonprofits that have been impacted by the pandemic and associated shutdowns can apply for loans through the state's newly revamped and expanded Small ...
Apr. 14—COLUMBUS — The intruder who vandalized the Ohio Statehouse early Monday morning was in the building for about five minutes — breaking three windows, emptying the contents of a fire extinguisher into the massive rotunda, and using a phone — without being interrupted by security. At no point did Jeremy D. Ibanez, 36, of Columbus come into contact with any Ohio State Highway Patrol ...
Apr. 14—ALBUQUERQUE, N.M. — Master planned community Mesa del Sol could continue to play a big role in the city and state's economic growth, the organization's CEO said. "There's been a lot of buzz about Mesa del Sol lately, but the project began in the '80s and it's taken 40 years for us to become an overnight success," Mesa del Sol CEO David Campbell said during an Albuquerque Economic Forum ...
Apr. 14—An artifact is a term we use in the industry for physical objects that have a cultural or historical significance. But, the term has a way of making those pieces sound ancient. Distant. Out of touch. It's like they are of a time that is so far removed from the present that the connection between them and us is no longer cohesive. History is funny that way. Heck, time is funny that way. ...